- Amgen recently received a positive opinion from the European Medicines Agency’s CHMP to expand Repatha’s use to adults with or at high risk for atherosclerotic cardiovascular disease in Europe, following Phase 3 VESALIUS-CV data showing meaningful reductions in first major cardiovascular events and LDL-C levels.
- This expanded cardiovascular prevention use, if approved by the European Commission, could broaden Repatha’s eligible patient pool and reinforce Amgen’s position in treating high-risk primary prevention populations where many patients still do not reach guideline-recommended LDL-C targets despite existing therapies.
- We’ll now examine how the potential European expansion of Repatha for high-risk cardiovascular prevention reshapes Amgen’s investment narrative and risk profile.
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
Amgen Investment Narrative Recap
To own Amgen, you need to believe its broad biologics portfolio and late stage pipeline can offset pricing pressure and biosimilar headwinds while funding heavy R&D. The potential Repatha label expansion in Europe strengthens Amgen’s cardiovascular story but does not fundamentally change the near term risk that higher investment and pricing pressure could squeeze margins, nor the importance of execution on late stage assets as a key catalyst.
The recent Q2 2026 results are particularly relevant here. Solid reported revenue of US$10,054 million and net income of US$2,375 million help show how existing products, including Repatha, contribute to earnings power that funds ongoing cardiovascular trials and potential indication expansions. This earnings base is central to how much room Amgen has to absorb pricing pressure, support its dividend, and continue investing behind assets that could become the next major growth drivers.
However, beneath this progress, investors should still pay close attention to rising R&D spend and the risk that late stage trials like VESALIUS CV may not always translate into...
Read the full narrative on Amgen (it's free!)
Amgen's narrative projects $41.5 billion revenue and $10.3 billion earnings by 2029.
Uncover how Amgen's forecasts yield a $371.93 fair value, a 9% downside to its current price.
Exploring Other Perspectives
Some higher end analysts were already assuming Amgen could reach about US$44.4 billion in revenue and US$13.2 billion in earnings by 2029, which is a far more optimistic path than the baseline view tied mainly to steady demand and pricing risk. With the new Repatha news, you can now weigh whether that bullish pipeline led growth story, and the risk of acquisitions not delivering as expected, still looks realistic or needs updating.
Explore 5 other fair value estimates on Amgen - why the stock might be worth as much as 59% more than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Amgen research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.
Contemplating Other Strategies?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Find 51 companies with promising cash flow potential yet trading below their fair value.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com